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Abstract Aortic stenosis (AS) is the most common prima-
ry valve disorder in the elderly with an increasing preva-
lence. It is increasingly clear that it is also a disease of the
left ventricle (LV) rather than purely the aortic valve. The
transition from left ventricular hypertrophy to fibrosis re-
sults in the eventual adverse effects on systolic and diastol-
ic function. Appropriate selection of patients for aortic
valve intervention is crucial, and current guidelines recom-
mend aortic valve replacement in severe AS with symp-
toms or in asymptomatic patients with left ventricular
ejection fraction (LVEF) <50 %. LVEF is not a sensitive
marker and there are o ther parameters used in
multimodality imaging techniques, including longitudinal
strain, exercise stress echo and cardiac MRI that may assist
in detecting subclinical and subtle LV dysfunction. These
findings offer potentially better ways to evaluate patients,
time surgery, predict recovery and potentially offer targets
for specific therapies. This article outlines the pathophysi-
ology behind the LV response to aortic stenosis and the role
of advanced multimodality imaging in describing it.
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Introduction
Aortic stenosis (AS) is the most common left-sided valve le-
sion [1], and moderate or severe AS affects more than one in
eight people over 75 [2]. Current indications for aortic valve
replacement are based around the severity of stenosis, or in
asymptomatic patients with evidence for left ventricular com-
promise (ejection fraction (LVEF) < 50 %). Aortic interven-
tion is also indicated for those who exhibit symptoms during
exercise or who are undergoing cardiac surgery for other in-
dications [3••, 4]. Historically, the majority of patients with
severe AS receiving aortic valve replacement exhibited a high
transvalvular gradient, with variable left ventricular hypertro-
phy and normal or reduced LVEF. Populations with lower
gradient yet still severe aortic stenosis are increasingly
recognised in situations of low flow either characterised by
an impaired ejection fraction (classical low flow-low gradient
aortic stenosis) or a normal ejection fraction (paradoxical low
flow-low gradient aortic stenosis) [5]. The previous assump-
tion has been that patients progress from normal systolic func-
tion and high gradients through to impaired function and low
flow, hence low gradients. This is now considered to be at
best an oversimplification and at worst erroneous as the
development of these ultimate severe AS phenotypes ap-
pears to follow different antecedent pathological pathways
[6]. This illustrates that this disease is highly dependent on
the responses of the myocardium and vasculature [7–9].
This response is complex and consists of a combination
of wall thickening, change in cavity size and fibrosis, with
the associated effects on systolic and diastolic function
[10]. This is further complicated by comorbidity associated
with progressive ageing, in particular coronary artery dis-
ease, hypertension, diabetes and the progressive decreases
the compliance of the vascular bed.
Classical Aortic Stenosis
In classical aortic stenosis, a longstanding increase in global
LVafterload results in concentric LV hypertrophy [11] and an
elevation of end-diastolic pressure [12]. This hypertrophy is
the main compensatory mechanism in the early phase of the
disease, limiting wall stress and maintaining normal endocar-
dial shortening [13] by offsetting the raised intracavity pres-
sure [10]. Cardiac output and LV filling pressures may remain
within normal limits despite very high pressures. This is
characterised by a slow increase in transvalvular gradient until
finally flow drops and the gradient start to reduce. The chang-
es in the extracellular collagen matrix and a decrease in myo-
cardial perfusion pressure eventually lead to subendocardial
ischaemia [14], resulting in myocardial apoptosis and fibrosis
[11]. In addition, many factors including age [15], sex [16],
genetic factors, hypertension and the presence of coronary
artery disease influence ventricular behaviour and remodel-
ling. The additive effect of concomitant systemic hypertension
leads to a significant increase in left ventricular systolic wall
stress, which further increases the global afterload. The result
is further impairment of myocardial function leading to re-
duced survival [17] with increased perioperative complica-
tions and mortality [18, 19].
Non-classical Aortic Stenosis Progression
This description with the progression of severe aortic stenosis
through compensatory mechanisms resulting in a high gradi-
ent followed by left ventricular failure resulting in a reduction
in gradient is attractive but unfortunately does not describe the
majority of patients destined to develop severe AS with a low
transvalvular gradient, whether or not the ejection fraction is
preserved or impaired. A proportion of such patients demon-
strate excessive left ventricular hypertrophy [20]. Dahl et al.
demonstrated that in patients with LFLGAS (low flow, low
gradient aortic stenosis), only 5 % had evidence of previous
high gradient disease. In these patients with LFLGAS, there
was a gradual increase in wall thickness, reduction in end
diastolic diameter and small reduction in EF, over a 5-year
follow-up period. The results suggest that LFLG AS with
preserved LVEF is not an end-stage high-gradient disease
but a separate entity characterised in part by progressive mal-
adaptive LV remodelling [21]. The pathology that defines
which way the disease will request remains to be fully
described.
Factors Affecting the Left Ventricular Response
to AS
When the limit of sarcomere extension and diastolic stiff-
ness is reached, the Badaptive^ mechanisms to pressure
overload are exceeded. The left ventricle becomes unable
to maintain a normal stroke volume in the setting of limited
preload reserve, a condition known as Bafterload mis-
match^. The afterload mismatch state definition, however,
implies that myocardial contractility is not depressed and
that LV size and function will recover, once the valvular
obstruction is relieved [22]. A potential underlying mech-
anism involving the transition from left ventricular
hypertrophy/high afterload states to heart failure is the in-
crease in LV filling pressure leading to increased left atrial
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wall tension and myocyte stretch. In imaging, this is ob-
served by deterioration in diastolic properties that improve
after correction of the obstruction [23] which is closely
related to clinical outcome [24]. The magnitude and chro-
nicity of the increased LV filling pressure are associated
with an increase in left atrial size [25], which has been
shown to predict postoperative symptomatic improvement
[26] and subsequent prognosis [27]. This process results in
fibrosis, apoptosis and, in turn, atrial enlargement [28].
The amount of myocardial fibrosis and myocardial degen-
eration affects systolic and diastolic function [11, 29] and
appears to have a significant effect on clinical status and
long-term survival after aortic valve replacement [30], sug-
gesting at least partially irreversible remodelling.
Patterns of Remodelling
The ventricular hypertrophic adaptation follows four well-
recognised mechanistic patterns: normal ventricular ge-
ometry, concentric remodelling, concentric hypertrophy
and eccentric hypertrophy [31]. Concentric remodelling
is defined by a normal left ventricular mass and an in-
creased relative wall thickness and concentric hypertrophy
by a combination of left ventricular hypertrophy and in-
creased relative wall thickness [10]. There is evidence to
suggest that adaptive remodelling becomes maladaptive
with increasing LV hypertrophy and consequent myocar-
dial fibrosis. A study by Cioffi et al. showed that over
10 % of patients with asymptomatic severe AS exhibited
inappropriate left ventricular hypertrophy (LVH) and
these patients had a 4.5-fold higher risk of death, aortic
valve replacement (AVR) or hospital admission [20].
Echocardiographic studies, however, have also demon-
strated that 10–20 % of patients with aortic stenosis do
not have left ventricular hypertrophy [32, 33]. The sever-
ity of AS has been shown to be unrelated to the pattern of
hypertrophy, supporting the multifactorial nature of LV
remodelling [34]. In LFLGAS, longitudinal myocardial
shortening is affected to a larger extent due to a more
advanced fibrosis in the subendocardial layer, where the
fibres are oriented longitudinally [35, 36]. It is associated
with concomitant systemic hypertension in around 77 %
of patients [37], which may induce a low flow state de-
spite normal LV ejection fraction. The LV therefore faces
a double afterload due to the valvular load due to the AS
and an arterial load, as a consequence of reduced arterial
compliance. Paradoxical (preserved EF) low flow low
gradient AS is characterised by a restrictive physiology,
more pronounced LV remodelling and myocardial fibrosis
contributing to a reduction in size, compliance and filling
of the LV [5, 38]. The advanced fibrosis in the subendo-
cardial layer is associated with a reduction in longitudinal
shortening. These patients have a worse prognosis than
those with moderate AS or normal flow severe AS [17,
39]. The prognosis of these patients is also worse if treat-
ed medically rather than surgically. A study by Barash
found a 2-fold increase in mortality and an almost 50 %
lower referral rate for AVR in the low gradient AS com-
pared to the high gradient AS group [40]. Hachicha et al.
studied the data of 512 patients with severe aortic stenosis
and found that compared with normal flow aortic stenosis,
the overall 3-year survival was lower in patients with low
flow AS [17].
The Role of Advanced Imaging
Defining Severe AS
For the purposes of patient care severe, AS is usually defined
as a calculated aortic valve area of <1.0 cm2 (or <0.65/m2)
corroborated by a peak aortic jet velocity of >4.0 m/s and a
mean transvalvular pressure gradient of >40 mmHg [3••, 4].
The classification of stenotic severity is not always so straight-
forward, and the echocardiographic findings are discordant in
one in three patients [41, 42], the most frequent being a valve
area in the severe range with a low mean gradient <40 mmHg,
suggesting a lesser severity of AS. Here, a distinction needs to
be made between those with low flow (conventionally consid-
ered <35 mls/m2) and frequently low ejection fraction, and
those with normal flow, in whom measurement inaccuracy
or the inherent discordance between a mean gradient of
40 mmHg and a valve area of 1.0 cm2, are the more likely
explanations. Ensuring the correct definition of severe AS
remains an important challenge both clinically and also in
critical evaluation of the literature [43].
Transthoracic Echocardiography
Transthoracic echocardiographic assessment includes mea-
sures of AS severity, LV function and LV wall thickness,
and cavity dimensions and ejection fraction should be based
on existing recommendations [44••, 45••]. Parameters describ-
ing aortic stenosis severity include transvalvular velocity and
mean gradient measured from continuous wave Doppler
through the left ventricular outflow tract and aortic valve.
Particular care should be made to interrogate this signal from
multiple positions on the left and right side of the chest: Up to
61 % of patients do not have their highest signal from the
conventional apical position [46]. Both of the measurements
are heavily flow dependent, and a variety of approaches are
employed to correct for this. The principle among these is the
use of the continuity equation to correct for sub-aortic flow.
This provides the calculation for the aortic valve area. It re-
quires a measurement of the left ventricular outflow tract
Curr Cardiol Rep (2016) 18: 80 Page 3 of 9 80
(LVOT) areas estimated from its diameter using the equation
[47]. This may be a major source of error as small errors are
squared; furthermore, the LVOT is usually elliptical in severe
AS [48, 49]. The dimensionless index where the ratio of the
sub-aortic and transaortic flow is described attempts to cir-
cumnavigate this [50, 51]. Other measures such as stroke
work loss have been shown to obviate the assessment of
transvalvular flow and appear to be more stable than the
Gorlin valve area in the assessment of stenotic valve lesions
[52–54], and measurement of valvular resistance (the ratio of
transvalvular gradient to flow) has also been proposed as a
valid method for quantification of aortic stenosis severity
[55, 56]. A further Doppler parameter, the energy loss index
(ELI) has been shown to provide independent and incremental
prognostic information than that derived from the convention-
al markers of aortic stenosis severity, in asymptomatic patients
with aortic stenosis [57].
Decreasing flow may be due to an increase in global LV
afterload not only due to the valvular stenosis but also from a
decrease in systemic arterial compliance and/or increased vas-
cular resistance [58, 59]. Assessment of the global LV haemo-
dynamic load by measuring the valvuloarterial impedance
(Zva) was proposed by Pibarot and co-workers [60] and is
defined as the ratio of the estimated LV systolic pressure
(i.e. the sum of the systolic arterial pressure (SAP) and mean
pressure gradient (MPG) to the stroke volume indexed (SVi)
for body surface area [61]. The Zva has been shown to be
superior to the standard parameters of AS severity such as
transvalvular gradients and effective orifice area in predicting
LV dysfunction and clinical outcomes [27, 62, 63].
Dichotomising function using ejection fraction is a major
oversimplification as those with small cavity size (due to ei-
ther habitus or hypertrophy), or significantly impaired long
axis function may also develop low flow. Deformation imag-
ing (strain and strain rate) using speckle-tracking echocardi-
ography has been shown to be more sensitive than LVEF in
detecting myocardial contractility [36, 64]. Two-dimensional
speckle tracking echocardiography (2D-STE) shows the de-
formation of the left ventricular muscle in three directions:
longitudinal, circumferential and radial. Studies in patients
with severe AS and preserved LVEF confirm that the decrease
in LV longitudinal strain [65, 66] predicts events in asymp-
tomatic patients, as well as mortality [67]. Impaired strain
prior to valve replacement predicts worse postoperative out-
come with respect to rehospitalisation for heart failure and
overall mortality [68]. Global longitudinal strain (GLS) ap-
pears to be a more robust parameter in the assessment of
subclinical LV dysfunction. GLS is decreased in AS patients
and is even more affected in severe AS patients as compared
to patients with moderate AS [69, 70]. Patients with LV lon-
gitudinal strain ≤15.9 % have an excess risk of death, symp-
toms or surgery that was more than twice that of patients with
preserved longitudinal function [71]. In asymptomatic
patients with severe AS and preserved LV ejection fraction, a
significant decrease in LV longitudinal strain (especially in the
basal segments) signals a reduced exercise capacity and an
increased risk of cardiac events was observed during follow-
up in patients with lower values of longitudinal strain in the
LV basal segments (below −13%), while a GLS below −18%
predicted an abnormal exercise response with a sensitivity of
68 % and a specificity of 77 % [72].
Further information can be gained by increasing flow
through the valve using low-dose dobutamine stress echo
(DSE) (class IIa indication in managing patients with a re-
duced ejection fraction) [3••, 4]. It is likely that it offers infor-
mation in those with preserved EF, but this is less well
established. The assessment of LV flow reserve during low-
dose DSE has clear prognostic implications in true severe AS
[73, 74]. If a 20% increase in stroke volume is associated with
the development of a gradient of 40 mmHg or a peak velocity
of greater than 4 m/s, with an unchanging valve area, then the
AS is severe and intervention is warranted, while if no flow
recruitment is observed then the outlook from surgery is very
poor. Dobutamine stress echo has a critical role in
distinguishing between Btrue severe^ AS (due to the valve
itself) and pseudosevere AS, which is predominantly due to
myocardial disease. Pseudosevere AS will demonstrate an in-
crease in EOA but relatively little increase in gradient [5].
Those with pseudo severe disease are less likely to show a
favourable response to intervention. The TOPAS study inves-
tigators proposed to calculate the projected (effective orifice
area) EOA that would have occurred at a standardised flow
rate of 250 ml/s, and this new parameter of 1.2 cm2 has been
shown to be more closely related to actual AS severity, im-
pairment of myocardial blood flow, LV flow reserve and sur-
vival than traditional DSE parameters [75, 76].
Myocardial response during exercise may also be useful in
patients with severe ASwho claim to be asymptomatic or who
have equivocal symptoms [11], as is the assessment of
exercise-induced changes in LV systolic function, which can
provide prognostic information in patients with severe AS.
The absence of LV contractile reserve is characterised by the
absence or only small increase in LVEF and is associated with
exercise-induced symptoms and a markedly reduced midterm
cardiac event-free survival [77].
CMR
Two predominant types of myocardial fibrosis mediate the
transition from the initially adaptive hypertrophic response
to decompensation to heart failure. Diffuse or interstitial fibro-
sis reflects the more uniform nature of the condition, whereas
replacement fibrosis occurs later as the disease advances and
is characterised by a more focal distribution [78, 79].
Myocardial biopsy remains the gold standard for validating
myocardial fibrosis but is invasive, susceptible to sampling
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errors and unable to assess the fibrotic burden of the whole
heart. Cardiovascular magnetic resonance (CMR) is the only
non-invasive imaging modality that offers a direct, whole
heart assessment of myocardial fibrosis [80]. Late gadolinium
enhancement (LGE), for direct visualisation and quantifica-
tion of focal replacement fibrosis, and T1 mapping, for
assessing more diffuse patterns of interstitial fibrosis, are the
two approaches commonly used in this context [81].
LGE CMR is the most accurate way to visualise focal
midwall myocardial fibrosis [82, 83], which has been demon-
strated in 19 to 62% of patients with aortic stenosis [84, 85]. It
is mainly found in the subendocardial layer of the LV, and its
degree decreases from the base to the apex [86]. Its presence is
associated with adverse postoperative outcomes, in particular
not only residual symptoms but also mortality in patients un-
dergoing valve replacement [87, 88]. Lee et al. carried out a
prospective study of 118 patients with moderate and severe
AS. They found that patients with left ventricular systolic
dysfunction and LGE on CMR showed adverse structural
and functional remodelling, and in patients with normal LV
ejection fraction, LGE was associated with a stiffer ventricle,
suggesting that LGE CMRmay be useful in detecting subclin-
ical LV dysfunction in these patients [89]. A smaller study
carried out by Park et al. showed that the presence of LGE
had effects on poor improvement of LV filling pressure in
patients with severe AS. They also found that echocardio-
graphic parameters such as tissue Doppler imaging (TDI) E′
were associated with the presence of LGE, suggesting that
they may play a role in predicting long-term outcome and
improvement in LV remodelling after AVR [77]. The degree
of LGE has also been shown to correlate well with the degree
of histological fibrosis in these patients [90].
LGE relies on a difference in signal intensity between nor-
mal and focal regions of myocardial fibrosis and is therefore
not optimal for assessing interstitial fibrosis [91]. Diffuse in-
terstitial fibrosis is more uniformly distributed than focal re-
placement fibrosis and is emerging as a potential treatment
target, due to its reversibility. T1 mapping has emerged as a
novel CMR technique to assess this form of fibrosis [92], by
improving myocardial characterisation through its ability to
quantify signal intensity for each voxel in the myocardium
[93]. Several T1 mapping approaches have been developed
to quantify diffuse fibrosis. Extracellular volume fraction
(ECV), which corrects for blood pool and the plasma gadolin-
ium volume of distribution, offers the best reproducibility and
can predict outcomes as least as strongly as LV ejection frac-
tion [94, 95].
T1 mapping has been studied in patients with aortic steno-
sis, demonstrating the presence of diffuse fibrosis, severity of
aortic stenosis, LV mass and cardiac performance. A study by
Bull et al. showed increased T1 values in patients with severe
AS, with correlation with fibrosis on histology. Symptomatic
patients were more likely to demonstrate increased T1 values
compared to asymptomatic patients [81]. The degree of myo-
cardial fibrosis has also been shown to correlate with symp-
toms and LV function. Patients with severe fibrosis were less
likely to show improvement in symptoms, LV function and
LVH after surgery compared with those patients with mild to
moderate fibrosis [30]. A study by Treibel et al. used T1 map-
ping to investigate and correlate macroscopic and tissue level
patterns of LV remodelling in patients with severe AS (NCT).
They found that patients have differing patterns of remodel-
ling, with both native T1 and ECV correlating with prognostic
markers such as NT-pro-BNP [94].
The measurement of diffuse fibrosis has the potential to
improve therapeutic management in patients with aortic ste-
nosis, which may develop without symptoms or changes in
LV function. A subgroup of patients with severe AS benefit-
ing from early intervention may be identified.
Coexistent Amyloid in Aortic Stenosis
Recent case reports and case series have reported
coexisting cardiac amyloid in patients with severe aortic
stenosis—typically wild-type transthyretin (wtATTR)
[95–97]. Its prevalence and prognostic significance are
currently unknown but require further investigation be-
cause they may influence the management of AS in terms
of decisions surrounding intervention, procedure perfor-
mance and the use of specific amyloid therapies.
Computed Tomography
Cardiac computed tomography is heavily used in the clinical
work-up of patients undergoing transcatheter aortic valve im-
plantation (TAVI) in the assessment of aortic root, the thoracic
aorta and vascular access [98]. There is a strong linear rela-
tionship between the extent of calcification and severity of
aortic stenosis, which is often ignored in general CT chest
reporting [99]. This has been shown to predict the progression
of the condition and is particularly useful when ventricular
function is reduced and stress echocardiography is ambiguous
[100]. It is increasingly likely that calcification quantified by
CT will become a better gold standard for aortic stenosis se-
verity as it correlates very strongly with aortic weight [101].
Inflammation and calcification of the aortic valve are believed
to play a key role in predicting disease progression. Work
using 18F-NaF and 18F-FDG shows that activity of both
tracers is increased in patients with both aortic sclerosis and
stenosis, with a progressive rise in uptake with increasing
disease severity [102].
With regard to the myocardium, the assessment of LV
function and scar imaging by hyper enhancement post-
iodine contrast with cardiac CT is not routinely
established in clinical practice due to a high radiation
dose, but constant technical advances may make this
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modality more attractive in the future. Finally, in parallel
with the CMR T1 mapping technique, ECV can be cal-
culated using equilibrium contrast CT and may be an
attractive addition in patients not able to undergo CMR
[103].
A flow diagram describing the different patterns of ventric-
ular remodelling in aortic stenosis and the role of advanced
imaging is outlined in Fig. 1.
Conclusions
Aortic stenosis is a common lesion but with a complex
phenotype, which can make assessment challenging in
those patients with results that are discordant and/or flow
is reduced. The assessment of left ventricular function by
means of LVEF measurement is not adequate, and more
detailed evaluation of myocardial mechanics, myocardial
remodelling and flow is required to understand the pa-
thology and assess the likely benefit to be gained from
aortic valve intervention. Stress echocardiography, cardi-
ac MRI and PET/CT all provide diagnostic and prognos-
tic information, and an integrated multimodality ap-
proach to evaluation will identify those patients likely
to benefit from aortic valve intervention when the clini-
cal scenario is not clear cut. Follow-up for those with
moderate aortic stenosis needs to be more rigorous as
the previous assumptions that these patients would prog-
ress through the stage of high gradient before left ven-
tricular is erroneous.
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Fig. 1 Flow diagram illustrating the left ventricular effects of aortic stenosis and the role of advanced imaging modalities in their evaluation
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